Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review

• Main Authors: Zheng Yuan, Zhu Wei, Huang Xinjie, Lin Dongqun, Lin Yu
• Format: Article
• Language: English
• Published: De Gruyter 2021-08-01
• Series: Open Life Sciences
• Subjects: durvalumab; chemotherapy; neoadjuvant immunotherapy; locally advanced resectable nsclc; case report
• Online Access: https://doi.org/10.1515/biol-2021-0083

The benefit of immunochemotherapy in treating resectable locally advanced non-small cell lung cancer (NSCLC) is not well established. Here, we report a case of resectable stage III NSCLC treated with neoadjuvant immunotherapy combined with chemotherapy before surgery. A 61 years old man was admitted to our hospital due to paroxysmal cough and was diagnosed as squamous cell carcinoma T4N2M0 in the upper lobe of the right lung, which was locally advanced and resectable. He was treated with 3 courses of paclitaxel 250 mg intravenous (IV), carboplatin 0.65 g IV, and durvalumab 620 mg IV followed by thoracoscopic upper lobectomy and lymph node dissection. There was considerable regression of the tumor before surgery, and the patient achieved a complete pathological response after surgery. Our case study demonstrates the benefit of durvalumab and chemotherapy in the treatment of resectable locally advanced NSCLC.